Drug-resistance mechanisms and tuberculosis drugs

The Lancet

Volumn 385, Issue 9965, 2015, Pages 305-307

  Köser, Claudio U ^a   Javid, Babak ^a,b   Liddell, Kathleen ^a   Ellington, Matthew J ^c   Feuerriegel, Silke ^d,e   Niemann, Stefan ^d   Brown, Nicholas M ^c   Burman, William J ^f   Abubakar, Ibrahim ^c,g   Ismail, Nazir A ^h   Moore, David ^i,j   Peacock, Sharon J ^a,c,k,l   Török, M Estée ^a,c,k  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Tsinghua University ^*  (China)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Research Center Borstel   (Germany)

^e German Center for Infection Research   (Germany)

^f DENVER PUBLIC HEALTH   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^k CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^l WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEDAQUILINE; DELAMANID; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; CROSS RESISTANCE; DRUG INDUSTRY; DRUG MECHANISM; DRUG SENSITIVITY; GENOTYPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM; MYCOBACTERIUM CANETTII; MYCOBACTERIUM TUBERCULOSIS; NEXT GENERATION SEQUENCING; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; DRUG APPROVAL; GENETICS; HUMAN; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG APPROVAL; HUMANS; MUTATION; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84921520920     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62450-8     Document Type: Note

References (23)

1. AI Zumla, SH Gillespie, M Hoelscher et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects Lancet Infect Dis 14 2014 327 340
2. WA Wells, CC Boehme, FG Cobelens et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action Lancet Infect Dis 13 2013 449 458
3. A Somoskovi, V Bruderer, R Hömke, GV Bloemberg, EC Böttger A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment Eur Respir J 2014 10.1183/09031936.00142914 published online Oct 30.
4. RW Shafer, JM Schapiro Drug resistance and antiretroviral drug development J Antimicrob Chemother 55 2005 817 820
5. Food and Drug Administration Guidance for Industry. Role of HIV resistance testing in antiretroviral drug development (October 2007) http://www.fda.gov/downloads/Drugs/Guidances/ucm071173.pdf 2007 (accessed Dec 17, 2014).
6. Food and Drug Administration Guidance for Industry. Antiviral product development - conducting and submitting virology studies to the agency (June 2006) http://www.fda.gov/OHRMS/DOCKETS/98fr/05d-0183-gdl0002-01.pdf (accessed Dec 17, 2014).
7. CU Köser, S Feuerriegel, DK Summers, JA Archer, S Niemann Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance Antimicrob Agents Chemother 56 2012 6080 6087
8. K Andries, C Villellas, N Coeck et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline PLoS One 9 2014 e102135
9. K Andries, P Verhasselt, J Guillemont et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227
10. E Huitric, P Verhasselt, A Koul, K Andries, S Hoffner, D Andersson Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor Antimicrob Agents Chemother 54 2010 1022 1028
11. RC Hartkoorn, S Upekar, ST Cole Cross-resistance between clofazimine and bedaquiline through up-regulation of MmpL5 in Mycobacterium tuberculosis Antimicrob Agents Chemother 58 2014 2979 2981
12. Global Alliance for TB Drug Development Pipeline http://www.tballiance.org/downloads/Pipeline/TBA-Pipeline-Q3-2014-ICAAC.pdf 2014 (accessed Nov 11, 2014).
13. M Salfinger, A Somoskövi Multidrug-resistant tuberculosis and bedaquiline N Engl J Med 371 2014 2435 2436
14. S Feuerriegel, CU Köser, D Baù et al. Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824 Antimicrob Agents Chemother 55 2011 5718 5722
15. DG Russell, CF Nathan Perspective: graduation time Nature 502 2013 S7
16. LP de Carvalho, G Lin, X Jiang, C Nathan Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance J Med Chem 52 2009 5789 5792
17. RW Shafer Rationale and uses of a public HIV drug-resistance database J Infect Dis 194 suppl 1 2006 S51 S58
18. AS Kesselheim, RM Cook-Deegan, DE Winickoff, MM Mello Gene patenting - the Supreme Court finally speaks N Engl J Med 369 2013 869 875
19. G Matthijs, I Huys, G Van Overwalle, D Stoppa-Lyonnet The European BRCA patent oppositions and appeals: coloring inside the lines Nat Biotechnol 31 2013 704 710
20. Nature Genetic rights and wrongs Nature 513 2014 143
21. W Shi, X Zhang, X Jiang et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333 2011 1630 1632
22. R Cook-Deegan, JM Conley, JP Evans, D Vorhaus The next controversy in genetic testing: clinical data as trade secrets? Eur J Hum Genet 21 2013 585 588
23. K Outterson New business models for sustainable antibiotics. Working group paper http://www.chathamhouse.org/publications/papers/view/197446 2014 (accessed Jan 7, 2015).